Akero Therapeutics Inc (AKRO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Akero Therapeutics Inc (AKRO) has a cash flow conversion efficiency ratio of -0.070x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-67.17 Million) by net assets ($957.64 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See AKRO equity to assets ratio to measure how much of total assets are equity-financed.
Akero Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Akero Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore AKRO long-term investments to assets to see how much of total assets are deployed in long-term investments.
Akero Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Akero Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Shuanghuan Driveline Co Ltd
SHE:002472
|
0.029x |
|
Travel + Leisure Co
NYSE:TNL
|
-0.037x |
|
Energy Fuels Inc
NYSE MKT:UUUU
|
0.011x |
|
PTT GLBL CHEM.-NVDR- BA10
F:GCB1
|
-0.057x |
|
Grupo Elektra S.A.B. de C.V
MX:ELEKTRA
|
0.144x |
|
Hubei Energy Group Co Ltd
SHE:000883
|
0.057x |
|
Shenzhen Sunlord Electronics Co Ltd
SHE:002138
|
0.053x |
|
Koninklijke Vopak NV
AS:VPK
|
0.127x |
Annual Cash Flow Conversion Efficiency for Akero Therapeutics Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Akero Therapeutics Inc from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see Akero Therapeutics Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $750.11 Million | $-230.11 Million | -0.307x | -12.96% |
| 2023-12-31 | $535.31 Million | $-145.37 Million | -0.272x | +4.15% |
| 2022-12-31 | $326.56 Million | $-92.52 Million | -0.283x | +39.87% |
| 2021-12-31 | $169.11 Million | $-79.68 Million | -0.471x | -72.17% |
| 2020-12-31 | $258.71 Million | $-70.80 Million | -0.274x | +1.12% |
| 2019-12-31 | $128.73 Million | $-35.63 Million | -0.277x | -398.72% |
| 2018-12-31 | $-49.92 Million | $-4.62 Million | 0.093x | -90.35% |
| 2017-12-31 | $-4.56 Million | $-4.38 Million | 0.960x | -- |
About Akero Therapeutics Inc
Akero Therapeutics, Inc. engages in developing transformational treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic… Read more